UNEW001Ai

General

Cell Line

hPSCreg name UNEWi001-A
Cite as:
UNEWi001-A (RRID:CVCL_9S37)
Alternative name(s)
UNEW001Ai
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UNEWi002-A
(UNEW002Ai, PRPF31 AW)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi027-A
(F116)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi004-A
(PRPF31 SH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi005-A
(PRPF31 RH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
ESi077-A
(CABi001-A, PRPF31-MiPS4F3)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis Pigmentosa
UNEWi003-A
(PRPF31-HD)
Donor diseases:
Retinitis pigmentosa
LUMCi056-A-1
(LUMC0128iCRB01 heterozygote CRISPR corrected isogenic clone 02, iso02LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
WTSIi691-A
(HPSI1116i-eiyy_1)
Donor diseases:
Retinitis pigmentosa
WTSIi693-A
(HPSI1116i-zies_2)
Donor diseases:
Retinitis pigmentosa
WTSIi698-A
(HPSI1116i-aimh_5)
Donor diseases:
Retinitis pigmentosa
WTSIi713-A
(HPSI0816i-xoga_7)
Donor diseases:
Retinitis pigmentosa
WTSIi693-B
(HPSI1116i-zies_6)
Donor diseases:
Retinitis pigmentosa
WTSIi698-B
(HPSI1116i-aimh_3)
Donor diseases:
Retinitis pigmentosa
WTSIi688-B
(HPSI1116i-wiau_4)
Donor diseases:
Retinitis pigmentosa
WTSIi613-B
(HPSI1116i-rafd_1)
Donor diseases:
Retinitis pigmentosa
WTSIi613-A
(HPSI1116i-rafd_4)
Donor diseases:
Retinitis pigmentosa
CIRMi525-A
(CW70348)
Donor diseases:
retinitis pigmentosa
FRIMOi002-A
(RP2_FiPS4F2.2)
Donor diseases:
Retinitis Pigmentosa
FRIMOi005-A
(RP3_FiPS4F11)
Donor diseases:
Retinitis Pigmentosa
WTSIi713-B
(HPSI0816i-xoga_12)
Donor diseases:
Retinitis pigmentosa
WTSIi688-A
(HPSI1116i-wiau_1)
Donor diseases:
Retinitis pigmentosa
WTSIi694-A
(HPSI0816i-oemk_6)
Donor diseases:
Retinitis pigmentosa
WTSIi463-A
(HPSI0716i-yibs_1)
Donor diseases:
Retinitis pigmentosa
RIi012-A
(RP.1.H.iPSC.2)
Donor diseases:
Retinitis pigmentosa
CIRMi508-A
(CW70323)
Donor diseases:
retinitis pigmentosa
WTSIi659-B
(HPSI1116i-wakr_6)
Donor diseases:
Retinitis pigmentosa
WTSIi610-A
(HPSI1116i-naum_5)
Donor diseases:
Retinitis pigmentosa
CIRMi519-A
(CW70342)
Donor diseases:
retinitis pigmentosa
MUi038-A
(EYS mutation)
Donor diseases:
retinitis pigmentosa
FRIMOi001-A
(RP1_FiPS4F1.6)
Donor diseases:
Retinitis Pigmentosa
LUMCi055-A
(CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CIRMi531-A
(CW70356)
Donor diseases:
retinitis pigmentosa
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CABi002-A
(OF0176-EYS02-C7, EYS02-MiPS4F7)
Donor diseases:
Retinitis Pigmentosa
CIRMi542-A
(CW70373)
Donor diseases:
retinitis pigmentosa
IDVi001-A
(iPS-NR2E3-86)
Donor diseases:
Retinitis pigmentosa
WTSIi659-A
(HPSI1116i-wakr_3)
Donor diseases:
Retinitis pigmentosa
NUIGi027-A
(RP001C8)
Donor diseases:
Retinitis Pigmentosa
NUIGi028-A
(RP002C12)
Donor diseases:
Retinitis Pigmentosa
NUIGi029-A
(RP003C12)
Donor diseases:
Retinitis Pigmentosa
WTSIi463-B
(HPSI0716i-yibs_3)
Donor diseases:
Retinitis pigmentosa
RIi009-A
(RP2.H.iPSC.3)
Donor diseases:
Retinitis pigmentosa
Last update 15th February 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University of Newcastle (UNEW)
Owner Institute of Genetic Medicine
Distributors

External Databases

BioSamples SAMEA2629641
Cellosaurus CVCL_9S37
Wikidata Q54991151

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 45-49
Ethnicity Unknown

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
Severe
Genetic variants
PRPF31 (target)
19q13.42
PRPF31: c.522_527+10del
Disease associated phenotypes
  • Retinitis Pigmentosa
  • PRPF31
  • Age of onset: 15 years old
  • Night blindness at 15 years old
  • Decreased central vision by 30 years old
  • Current visual acuities 6/18 and 6/36 with refraction of -2 and bilateral posterior subcapsular cataracts
  • Bilateral extensive bone spicule pigmentation
  • attenuated arterioles
  • pale optic discs
Family history yes: two other members of the family show the same mutation with variable clinical phenotype

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes

External Databases (Donor)

BioSamples SAMEA2629629

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Contact information / weblink david.steel@ncl.ac.uk
Is there other documentation provided to the donor for consenting purposes? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided:
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? UNEW ethics committee
Approval number REC:11NE/0294
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? UNEW ethics committee
Approval number REC:11NE/0294
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: Can only be used for “eye disease research” due to restrictions mentioned in the original donor consent form.
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 45-49
Collected in 2013

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Other

Selection criteria for clones Stem cell morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-60
Yes
SSEA-1
No
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 27

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
XX

Other Genotyping (Cell Line)